

APAS® PHARMAQC BIOPHORUM PRESENTATION TO INDUSTRY LEADERS

Joint presentation with AstraZeneca highlighting positive preliminary performance data of APAS® PharmaQC

Adelaide, Australia, 7 February 2024: Australian medical technology company LBT Innovations Limited (ASX: LBT) (**LBT** or the **Company**), a leader in microbiology automation using artificial intelligence, is pleased to announce a joint webinar with AstraZeneca presenting APAS® PharmaQC to BioPhorum's industry working group for Alternative and Rapid Microbiology Methods. The webinar provided an opportunity to present to influential subject matter experts from many of the leading biopharmaceutical companies around the world.

Highlights:

- **APAS® PharmaQC performance data presented to biopharmaceutical industry subject matter experts**
- **Joint presentation with AstraZeneca, highlighting APAS® PharmaQC AI technology excellence**
- **Presentation builds awareness of APAS® PharmaQC with biopharmaceutical industry key opinion leaders**

The BioPhorum webinar presented the Company's APAS® PharmaQC solution for automated culture plate reading and included data from AstraZeneca's initial studies using the technology at its UK manufacturing facility. Importantly the data included examples where APAS® PharmaQC had been able to detect microbial growth missed in manual reading by two trained microbiologists, highlighting the value of the APAS® technology for this application.

The BioPhorum webinar was attended by pharmaceutical microbiology subject matter experts who are working together to investigate novel automation solutions for environmental monitoring culture plate reading. Industry presentations, such as this, form an important part of the Company's commercialisation strategy into the biopharmaceutical manufacturing industry, helping to build awareness of APAS® PharmaQC as an alternative to manual culture plate reading.

A copy of the presentation has been uploaded to the Company website: <https://www.lbtinnovations.com/apas-pharmaqc-ai-culture-plate-reading/>

Brent Barnes, CEO & Managing Director said:

"The presentation to BioPhorum provides a further opportunity to showcase APAS® PharmaQC within the biopharmaceutical manufacturing sector and engage with key opinion leaders within the industry. This builds on our presentations at PharmaLab and PDA Micro last year as we establish the APAS® PharmaQC brand and technology as an alternative to manual environmental plate reading."

About BioPhorum

A business-to-business membership organization, BioPhorum consists of ten "Phorums" leading more than 90 industry-changing initiatives with the help of 6,000 active subject matter experts. Established in 2008, BioPhorum brings leaders and subject matter experts together from across the biopharmaceutical and device industry to collaborate on challenges in existing and emerging topics that affect the whole industry including change notification, cybersecurity, extractables and leachables, forecast and demand planning, knowledge management, single-use systems, and sterile filtration.

Approved for release by the Chair of the LBT Board.

– ENDS –

About LBT Innovations

LBT Innovations (LBT) provides intelligent automation solutions to microbiology laboratories. Based in Adelaide, South Australia, the Company has developed a best-in-class technology, the Automated Plate Assessment System (APAS® Independence), using artificial intelligence and machine learning software to automate the imaging, analysis and interpretation of microbiology culture plates. The technology remains the only US FDA-cleared artificial intelligence technology for automated culture plate reading and is being commercialised through LBT's wholly owned subsidiary Clever Culture Systems AG (CCS). The product is currently being sold to microbiology laboratories in the pharmaceutical manufacturing sector for the reading of environmental monitoring culture plates and to clinical laboratories as an in vitro diagnostic for infectious diseases. Thermo Fisher Scientific, Inc is exclusive distributor of the APAS® Independence to clinical customers in the United States and selected countries in Europe.

INVESTOR ENQUIRIES

LBT Innovations
Brent Barnes Chief Executive Officer & Managing Director Tel: +61 8 8227 1555 E: info@lbtinnovations.com